TY - JOUR
T1 - Splenectomy, Interferon, and Treatments of Historical Interest in Hairy Cell Leukemia
AU - Habermann, Thomas M.
PY - 2006/10
Y1 - 2006/10
N2 - The evolution and "lessons learned" for therapeutic options and approaches in HCL, which subsequently evolved into the adenosine deaminase inhibitors as the treatment of choice, has been intriguing [74-77]. The contributions to patient care and individual patient lives have been remarkable [78]. Observation, splenectomy, and recombinant interferon are potential therapeutic alternatives in select patients as initial therapy, and as therapeutic alternatives in the 10% of patients who have progressive disease after the purine nucleoside analogs.
AB - The evolution and "lessons learned" for therapeutic options and approaches in HCL, which subsequently evolved into the adenosine deaminase inhibitors as the treatment of choice, has been intriguing [74-77]. The contributions to patient care and individual patient lives have been remarkable [78]. Observation, splenectomy, and recombinant interferon are potential therapeutic alternatives in select patients as initial therapy, and as therapeutic alternatives in the 10% of patients who have progressive disease after the purine nucleoside analogs.
UR - http://www.scopus.com/inward/record.url?scp=33748614085&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748614085&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2006.06.006
DO - 10.1016/j.hoc.2006.06.006
M3 - Review article
C2 - 16990108
AN - SCOPUS:33748614085
SN - 0889-8588
VL - 20
SP - 1075
EP - 1086
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 5
ER -